Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY Clinical therapeutics Pub Date : 2025-03-13 DOI:10.1016/j.clinthera.2025.02.005

De Bandt David MD, MSc , Johanna Mezence MD , Claire Rives Lange MD , Dominik Menges MD, PHD , Claire Carette MD, PHD

{"title":"Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study","authors":"De Bandt David MD, MSc , Johanna Mezence MD , Claire Rives Lange MD , Dominik Menges MD, PHD , Claire Carette MD, PHD","doi":"10.1016/j.clinthera.2025.02.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>The prevalence of type 2 diabetes has increased in France over the past decade, with changes in available pharmacologic treatments. This study aimed to assess trends in the sales of antidiabetic drugs in France over the last decade.</div></div><div><h3>Methods</h3><div>This retrospective cohort study used data from French national health insurance databases. Defined daily doses per 1000 inhabitants per day (DDD/TID), expenditures associated, and the proportion of the population receiving treatment were analyzed from January 2013 to December 2022.</div></div><div><h3>Results</h3><div>Between 2013 and 2022, the proportion of patients purchasing at least one antidiabetic drug per month increased from 3.07% to 4.12%, with average monthly consumption rising from 82.62 to 101.68 DDD/TID. Biguanides were the most sold antidiabetic drug, followed by sulfonylureas and insulin. The greatest increases in consumption and expenditures were observed for GLP-1 analogs and SGLT2 inhibitors.</div></div><div><h3>Conclusion</h3><div>The consumption and cost of antidiabetic drugs increased with the diabetes prevalence. GLP-1 analogs and SGLT2 inhibitors accounted for the main growth, reflecting their growing clinical adoption and evidence of efficacy, while sales of sulfonylureas and DPP4 inhibitors remained substantial despite concerns regarding their benefit-risk profiles. In 2022, expenditures for GLP-1 analogs surpassed insulin. These findings have implications for healthcare policy and resource allocation planning.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 5","pages":"Pages 371-376"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825000499","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The prevalence of type 2 diabetes has increased in France over the past decade, with changes in available pharmacologic treatments. This study aimed to assess trends in the sales of antidiabetic drugs in France over the last decade.

Methods

This retrospective cohort study used data from French national health insurance databases. Defined daily doses per 1000 inhabitants per day (DDD/TID), expenditures associated, and the proportion of the population receiving treatment were analyzed from January 2013 to December 2022.

Results

Between 2013 and 2022, the proportion of patients purchasing at least one antidiabetic drug per month increased from 3.07% to 4.12%, with average monthly consumption rising from 82.62 to 101.68 DDD/TID. Biguanides were the most sold antidiabetic drug, followed by sulfonylureas and insulin. The greatest increases in consumption and expenditures were observed for GLP-1 analogs and SGLT2 inhibitors.

Conclusion

The consumption and cost of antidiabetic drugs increased with the diabetes prevalence. GLP-1 analogs and SGLT2 inhibitors accounted for the main growth, reflecting their growing clinical adoption and evidence of efficacy, while sales of sulfonylureas and DPP4 inhibitors remained substantial despite concerns regarding their benefit-risk profiles. In 2022, expenditures for GLP-1 analogs surpassed insulin. These findings have implications for healthcare policy and resource allocation planning.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

法国十多年来的降糖药消费：一项观察性研究。

目的：过去十年来，随着现有药物治疗方法的变化，法国 2 型糖尿病的发病率也在上升。本研究旨在评估过去十年法国抗糖尿病药物的销售趋势：这项回顾性队列研究使用了法国国家医疗保险数据库中的数据。研究分析了2013年1月至2022年12月期间每千人每日的定义剂量（DDD/TID）、相关支出以及接受治疗的人口比例：2013年至2022年期间，每月至少购买一种抗糖尿病药物的患者比例从3.07%增至4.12%，月均用药量从82.62 DDD/TID增至101.68 DDD/TID。双胍类药物是销售量最大的抗糖尿病药物，其次是磺脲类药物和胰岛素。GLP-1 类似物和 SGLT2 抑制剂的消费量和支出增幅最大：结论：抗糖尿病药物的消费量和成本随着糖尿病发病率的增加而增加。GLP-1类似物和SGLT2抑制剂是主要的增长点，反映了它们在临床上越来越多的应用和疗效证据。2022 年，GLP-1 类似物的支出将超过胰岛素。这些发现对医疗保健政策和资源分配规划具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.